Table 1.
Author | Age | Sex | Site of primary disease | TNM stage | Treatment of primary disease | Timing of PEG placement (before or after primary therapy) | Time from PEG placement to stomal metastasis (months) | Other concurrent treatment failure sites | Treatment of PEG-site metastasis | Length of survival after PEG metastasis diagnosis (months) |
---|---|---|---|---|---|---|---|---|---|---|
Adelson
[17] |
63 |
M |
Oropharynx |
NA |
Surgery |
Before |
6 |
Lung, liver |
Chemo |
4 |
Ananth
[3] |
55 |
M |
Oral Cavity |
T1N2aM0 |
Surgery + XRT |
Before |
3.5 |
NCR |
Surgery + Chemo |
NED |
Balakrishnan
[18] |
50 |
M |
Larynx |
NA |
Surgery |
Before |
NA |
NCR |
Surgery |
NA |
Becker
[19] |
49 |
M |
Hypopharynx |
T4N3M0 |
XRT |
Before |
3 |
Lung |
Surgery |
5 |
Bhama
[20] |
51 |
M |
Hypopharynx |
T2N1M0 |
XRT |
Before |
3.5 |
Liver, pelvis |
Surgery |
4 |
Bushnell
[9] |
68 |
M |
Supraglottis |
T4N2bM0 |
Surgery + XRT |
After |
14 |
Lung |
None |
18 |
Chatni
[10] |
53 |
F |
Hypopharynx |
NA |
XRT |
After |
5 |
Neck |
None |
NA |
Coletti
[21] |
65 |
M |
Oral Cavity |
T4N2cM0 |
ChemoXRT |
Before |
9 |
NCR |
ChemoXRT |
2 |
Cossentino
[22] |
62 |
M |
Oropharynx |
T4N2M0 |
Surgery + XRT |
Before |
8 |
Lung |
None |
2 |
|
66 |
M |
Oropharynx |
T3N1M0 |
XRT |
Before |
9 |
NA |
None |
NA |
Cruz
[23] |
58 |
M |
Oral Cavity |
T4N0M0 |
XRT |
Before |
5 |
NA |
Surgery + Chemo |
4 |
|
48 |
M |
Hypopharynx |
T4N3M0 |
Surgery + ChemoXRT |
Before |
6 |
NA |
Surgery |
4 |
Daniels
[24] |
56 |
M |
Oral Cavity |
TxN+M0 |
Surgery + XRT |
Before |
3 |
NA |
Chemo + Surgery |
NA |
Douglas
[15] |
45 |
M |
Oropharynx |
T4N3M0 |
XRT |
Before |
3.5 |
NCR |
XRT |
9 |
Hawkin
[8] |
68 |
M |
Oropharynx |
T3N0M0 |
XRT |
Before |
14 |
NCR |
None |
1 |
Huang
[25] |
53 |
M |
Oropharynx |
T4N2aM0 |
Surgery + XRT |
Before |
6 |
NA |
NA |
NA |
Kurdow
[26] |
75 |
F |
Hypopharynx |
T4N0M0 |
XRT |
Before |
4 |
NA |
NA |
NA |
Laccourreye
[11] |
65 |
M |
Hypopharynx |
T3N0M0 |
ChemoXRT |
After |
11 |
Liver |
XRT |
4 |
Lee
[27] |
41 |
M |
Oropharynx |
T4N2bM0 |
Surgery + ChemoXRT |
Before |
13 |
Liver, spleen |
None |
1 |
Lim
[28] |
51 |
M |
Oropharynx |
T4N1M0 |
Surgery + XRT |
Before |
8 |
Lung |
Surgery |
NA |
Lin
[13] |
56 |
M |
Oropharynx |
T4N0M0 |
Surgery + XRT |
Before |
5 |
NCR |
NA |
2 |
Maccabee
[29] |
63 |
F |
Hypopharynx |
T4N1M0 |
ChemoXRT |
Before |
5 |
Primary site |
None |
3 |
Meurer
[30] |
45 |
M |
Oropharynx |
T3N1M0 |
Surgery |
Before |
12 |
Lung |
ChemoXRT |
17 |
|
76 |
F |
Oropharynx |
T2N0M0 |
XRT |
Before |
13 |
Lung |
Surgery |
16 |
Mincheff
[4] |
59 |
M |
Oropharynx |
T4N2bM0 |
Surgery + XRT |
NA |
4 |
NCR |
Surgery + XRT |
NA (Hospice) |
Potochny
[31] |
44 |
M |
Hypopharynx |
T2N2M0 |
Surgery + XRT |
Before |
9 |
NCR |
Surgery |
NED |
Preyer
[14] |
72 |
M |
Oropharynx |
T4N2cM0 |
ChemoXRT |
Before |
3 |
Lung |
None |
3 |
Purandare
[32] |
50 |
F |
Oropharynx |
T3N2M0 |
Surgery |
NA |
9 |
Primary site, neck |
NA |
NA |
|
62 |
M |
Oral Cavity |
T2N0M0 |
Surgery |
NA |
15 |
Primary site |
NA |
NA |
Schiano
[12] |
43 |
M |
Hypopharynx |
T4NxM0 |
Chemo |
After |
4 |
Primary site, neck |
NA |
NA |
Schneider
[33] |
61 |
F |
Oropharynx |
T4N0M0 |
Surgery + XRT |
Before |
10 |
NCR |
Surgery |
NED |
Sharma
[34] |
40 |
M |
Oral Cavity |
T4N3M0 |
ChemoXRT |
Before |
6 |
Primary site |
Surgery + Chemo |
NA (Hospice) |
Siddiqi
[35] |
56 |
F |
Supraglottis |
T3N2bM0 |
ChemoXRT |
Before |
7 |
NA |
NA |
2 |
Sinclair
[36] |
61 |
M |
Oropharynx |
T2N1M0 |
XRT |
Before |
5 |
Left axilla |
Surgery + ChemoXRT |
NA (recurrent disease detected) |
Thakore
[37] |
50 |
M |
Larynx |
NA |
Surgery + ChemoXRT |
NA |
NA |
Lung, hip, brain |
ChemoXRT |
6 |
Thorburn
[38] |
56 |
M |
Supraglottis |
T4N3M0 |
XRT |
Before |
11 |
NA |
NA |
1 |
Tucker
[16] |
NA |
NA |
Hypopharynx |
NA |
ChemoXRT |
Before |
3 |
NA |
NA |
NA |
Van erpecum
[39] |
69 |
M |
Hypopharynx |
T4N0M0 |
XRT |
Before |
10 |
NCR |
XRT + Surgery |
1 |
Current series |
69 |
M |
Hypopharynx |
T2N2aM0 |
ChemoXRT |
Before |
22 |
Adrenals, liver, lung |
Chemo XRT |
8 |
|
77 |
M |
Supraglottis |
T3N1M0 |
ChemoXRT |
Before |
16 |
NCR |
Chemo |
5 |
|
46 |
M |
Oral Cavity |
T4N1M0 |
ChemoXRT |
Before |
8 |
NCR |
Surgery |
19 |
|
64 |
M |
Oropharynx |
T1N2cM0 |
XRT |
Before |
7 |
Primary site, neck |
Surgery |
NED |
Total cases | 42 |
Abbreviations: NA, not available; Chemo, Chemotherapy; XRT, radiation therapy; NCR, no concurrent recurrence; NED, no evidence of disease.